- Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group. [Journal Article]
- EPEur Psychiatry 2018 Aug 17; 54:71-76
- CONCLUSIONS: The new diagnostic criteria for apathy provide a clinical and scientific framework to increase the validity of apathy as a clinical construct. This should also help to pave the path for apathy in brain disorders to be an interventional target.
- Cognition among individuals along a spectrum of increased risk for Parkinson's disease. [Journal Article]
- PlosPLoS One 2018; 13(8):e0201964
- CONCLUSIONS: Among individuals across a spectrum of risk for PD, cognitive function is worse among those with the characteristic most strongly associated with future risk of PD or dementia with Lewy bodies, namely RBD.
- Psychiatric Aeromedical Evacuations of Deployed Active Duty U.S. Military Personnel During Operations Enduring Freedom, Iraqi Freedom, and New Dawn. [Journal Article]
- MMMil Med 2018 Aug 14
- CONCLUSIONS: Psychiatric conditions are one of the leading reasons for the aeromedical evacuation of active duty military personnel from the military combat theater. For many active duty military personnel, a psychiatric aeromedical evacuation from a combat theater is the start of a military career-ending event that results in separation from active duty. This finding has important clinical and operational implications for the evaluation and treatment of psychiatric conditions during military deployments. Whenever possible, deployed military behavioral health providers should attempt to treat psychiatric patients in theater to help them remain in theater to complete their operational deployments. Improved understanding of the factors related to psychiatric aeromedical evacuations will provide important clinical and policy implications for future conflicts.
- 5-HT1A receptor ligands and their therapeutic applications: review of new patents. [Journal Article]
- EOExpert Opin Ther Pat 2018 Aug 20
- 5-HT1AR was one of the first discovered serotonin receptors and is one of the most thoroughly studied. Dysfunctions associated with 5-HT1AR neurotransmission are linked to several psychiatric disorde...
5-HT1AR was one of the first discovered serotonin receptors and is one of the most thoroughly studied. Dysfunctions associated with 5-HT1AR neurotransmission are linked to several psychiatric disorders, including anxiety, depression and movement disorders. Areas covered: The current review covers patent literature published between January 2012 and May 2018. Queries were performed on Espacenet, SciFinder, clinicaltrials.gov, pharmacodia.com and the websites of pharmaceutical companies. Expert opinion: Several novel therapeutic applications have been proposed for 5-HT1AR ligands, i.e., prostate cancer treatment, gastrointestinal and cardiopulmonary disorders, facilitation of urination and defecation and L-DOPA-induced dyskinesia. Interestingly, no patent application has been filed by Big Pharma companies, while numerous research is being conducted in smaller companies and academia.
- Association between Upper Respiratory Infection and Idiopathic Unilateral Vocal Fold Paralysis. [Journal Article]
- AOAnn Otol Rhinol Laryngol 2018 Aug 20; :3489418787542
- CONCLUSIONS: This study suggests that symptoms of upper respiratory infection frequently occur with the presentation of IUVFP. The onset of symptoms tended to occur between December and February. The mechanism of viral-mediated UVFP has not been established. Future studies to explore this pathophysiology are needed.
- Sleep Paralysis, a Medical Condition with a Diverse Cultural Interpretation. [Journal Article]
- IJInt J Appl Basic Med Res 2018 Jul-Sep; 8(3):137-142
- Sleep paralysis (SP) is a state associated with the inability to move that occurs when an individual is about sleeping or just waking. It could occur in healthy individuals as isolated SP. It has als...
Sleep paralysis (SP) is a state associated with the inability to move that occurs when an individual is about sleeping or just waking. It could occur in healthy individuals as isolated SP. It has also been linked with other underlying psychiatry, familial, and sleep disorders. Statistics show that 8% of the general population suffers from SP. Although this value has been described inaccurately, there is no standard definition or etiology to diagnose SP. There are several speculations describing SP in the current literature. These descriptions can be viewed as either cultural-based or medical-based. The disparity among cultural or ethnic groups and medical professionals in identifying SP has led to the various approaches to managing the condition. This review aims to medically describe SP and how it is interpreted and managed among various cultural groups.
- SCA2 presenting as a focal dystonia. [Journal Article]
- JCJ Clin Mov Disord 2018; 5:6
- CONCLUSIONS: We describe a patient with SCA2 who presented with focal dystonia of the right upper extremity. Subtle cerebellar signs as well as the family history became especially important given the absence of predominant gait ataxia. Our case emphasizes that focal dystonia is not only a feature of SCA2, but can also rarely be the presenting sign as well as the most prominent feature during the disease course.
- Validation of abnormal glucose metabolism associated with Parkinson's disease in Chinese participants based on 18F-fluorodeoxyglucose positron emission tomography imaging. [Journal Article]
- NDNeuropsychiatr Dis Treat 2018; 14:1981-1989
- CONCLUSIONS: This dual-center study demonstrated the high comparability and reproducibility of PD-related cerebral metabolic activity patterns across independent Chinese cohorts and may serve as an objective diagnostic marker for the disease.
- Optical Coherence Tomography Findings in Patients of Parkinson's Disease: An Indian Perspective. [Journal Article]
- AIAnn Indian Acad Neurol 2018 Apr-Jun; 21(2):150-155
- CONCLUSIONS: There is generalized retinal nerve degeneration in patients of PD and the degree of loss correlated with the severity and duration of disease.
New Search Next
- Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials. [Review]
- CPClin Psychopharmacol Neurosci 2018 Aug 31; 16(3):235-245
- Atypical antipsychotics (AAPs) are increasingly used for the treatment of psychotic disorders but are known to be associated with metabolic abnormalities. This study is a systematic review and meta-a...
Atypical antipsychotics (AAPs) are increasingly used for the treatment of psychotic disorders but are known to be associated with metabolic abnormalities. This study is a systematic review and meta-analysis of randomized controlled trials (RCTs) studying the effectiveness of melatonin for the amelioration of AAP-induced metabolic syndrome. The MEDLINE (accessed via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials, PsycINFO, LILACS, CINAHL, and OpenGrey databases were searched for RCTs without language restrictions. Inclusion criteria were randomized, double-blind clinical trials comparing melatonin or melatonin agonists with placebo for the amelioration of AAP-induced effects at any age with selected components of metabolic syndrome as outcome measures. Two reviewers independently selected articles and assessed quality using Cochrane risk of bias and concealment tools. Of 53 records, five RCTs were eligible for the systematic review and three for the meta-analysis. The meta-analyses showed no statistically significant difference in any anthropometric or metabolic variable considered. Analysis according to psychiatric diagnosis from one RCT showed significant decreases in diastolic blood pressure (5.5 vs. -5.7 mmHg for the placebo and melatonin groups, respectively; p =0.001), fat mass (2.7 vs. 0.2 kg, respectively; p =0.032), and triglycerides (D) (50.1 vs. -20 mg/dl, respectively; p =0.08) in the bipolar group but not the schizophrenia group. Although limited to five RCTs with small sample sizes, evidence from RCT indicates that melatonin improves AAP-induced metabolic syndrome. This beneficial effect seems more significant in patients with bipolar disorder than those with schizophrenia. Further RCTs are needed to definitively establish the potential ameliorative effect of melatonin and to justify its efficacy as an add-on therapy to curtail AAP-induced metabolic syndrome.